TRASTUZUMAB (Herceptin) prior authorization at Blue Cross Blue Shield of Michigan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Blue Cross Blue Shield of Michigan requires HER2/neu Receptor Antagonist prior-authorization documentation for TRASTUZUMAB (Herceptin): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Blue Cross Blue Shield of Michigan reviews TRASTUZUMAB (Herceptin) prior authorizations against its medical policy for HER2/neu Receptor Antagonist. Blue Cross Blue Shield of Michigan-specific context: Largest insurer in Michigan (~4.5M members). Statutory non-profit mutual. Switched PBM from Express Scripts to OptumRx effective January 2024 — appeals around 2024-2025 may involve formulary disruption. Michigan DIFS oversight.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in HER2/neu Receptor Antagonist
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Blue Cross Blue Shield of Michigan's medical policy URL referenced in the cover letter
Blue Cross Blue Shield of Michigan's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Step therapy via OptumRx (PBM since 2024)
- Site-of-care reductions for infusions
- Behavioral health prior auth
- OON balance bill disputes
TRASTUZUMAB (Herceptin)-specific denial patterns and context
Across payers (not just Blue Cross Blue Shield of Michigan), TRASTUZUMAB (Herceptin)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Plan-mandated biosimilar switch mid-treatment
- HER2 IHC 2+ with FISH equivocal — plan demands IHC 3+
- Adjuvant duration beyond 1 year
- Site-of-care reduction
Brand: Herceptin. Reference biologic for HER2-positive breast and gastric cancer. Biosimilars: Kanjinti, Trazimera, Ogivri, Ontruzant, Herzuma. Also a component of Enhertu (trastuzumab deruxtecan, separate molecule) and Kadcyla.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Blue Cross Blue Shield of Michigan denial sticks and the patient needs bridge access while appealing.
How Blue Cross Blue Shield of Michigan approaches Biosimilars PAs
Blue Cross Blue Shield of Michigan's Biosimilars reviewer typically anchors TRASTUZUMAB (ONTRUZANT) prior-auth decisions on step therapy via optumrx (pbm since 2024) and site-of-care reductions for infusions. Pharmacy-benefit review for TRASTUZUMAB (ONTRUZANT) at Blue Cross Blue Shield of Michigan is routed through OptumRx (switched from Express Scripts January 2024). The 30-day standard review window starts when the prior-authorization request is received with all required documentation — incomplete packets pause the clock and add 5-10 days to time-to-approval, after which the 180-day internal-appeal window begins from the denial date. Blue Cross Blue Shield of Michigan treats interchangeability designation and prescriber "dispense-as-written" language as the two pivot points for biosimilar-vs-reference disputes. Blue Cross Blue Shield of Michigan is domiciled in MI, so unresolved appeals escalate to the MI insurance department's external-review program for fully-insured policies (self-funded ERISA plans route to the DOL EBSA instead). Largest insurer in Michigan (~4.
If the PA is denied
Blue Cross Blue Shield of Michigan gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://providers.bcbsm.com) with the same packet plus a peer-reviewed citation supporting TRASTUZUMAB (Herceptin)for the patient's indication.
Contact Blue Cross Blue Shield of Michigan
- Provider portal: https://providers.bcbsm.com
Frequently asked questions
What documentation does Blue Cross Blue Shield of Michigan need for TRASTUZUMAB (Herceptin) prior auth?
Blue Cross Blue Shield of Michigan's typical PA packet for TRASTUZUMAB (Herceptin): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For HER2/neu Receptor Antagonist, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Blue Cross Blue Shield of Michigan?
Standard TRASTUZUMAB (Herceptin) PA decisions at Blue Cross Blue Shield of Michigan: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Blue Cross Blue Shield of Michigan most often reject TRASTUZUMAB (Herceptin) for?
Across Blue Cross Blue Shield of Michigan's book the common rejection patterns include: Step therapy via OptumRx (PBM since 2024); Site-of-care reductions for infusions; Behavioral health prior auth. For TRASTUZUMAB (Herceptin) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
Can Blue Cross Blue Shield of Michigan force a mid-treatment switch from the reference biologic to TRASTUZUMAB (ONTRUZANT)?
Blue Cross Blue Shield of Michigan can require biosimilar use at initiation, but mid-treatment forced switches face higher appeal-reversal rates when the chart documents a stable patient, a defined transition-of-care concern, or prescriber "dispense-as-written" intent supported by a clinical rationale (immunogenicity history, nocebo response in prior switches, narrow therapeutic window). Cite the FDA Purple Book interchangeability designation when arguing the switch — interchangeable biosimilars permit pharmacy substitution; non-interchangeable biosimilars do not. Pharmacy-benefit handling is routed through OptumRx (switched from Express Scripts January 2024). External-review escalation for Blue Cross Blue Shield of Michigan fully-insured policies sits with the MI insurance department.
How do I prep for a peer-to-peer with Blue Cross Blue Shield of Michigan on TRASTUZUMAB (Herceptin)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
- Adalimumab at Blue Cross Blue Shield of Michigan
- Aflibercept at Blue Cross Blue Shield of Michigan
- Apixaban at Blue Cross Blue Shield of Michigan
- Atezolizumab at Blue Cross Blue Shield of Michigan
- TRASTUZUMAB (Herceptin) at UnitedHealthcare
- TRASTUZUMAB (Herceptin) at Elevance Health
- TRASTUZUMAB (Herceptin) at Aetna
Generate the TRASTUZUMAB (Herceptin) PA packet
Open ApprovalHelp — generate a TRASTUZUMAB (Herceptin) prior-auth packet tailored to Blue Cross Blue Shield of Michigan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com